EGFR and glioblastoma: Mutation or overexpression of EGFR occurs in many cancers, including lung cancer and glioblastoma, and the EGFR is the target of small molecule inhibitor drugs, such as erlotinib and gefitinib, as well as EGFR-binding antibodies (see Reference [55] for a review of the roles of the EGFR in cancer).